CNO Financial Details Strong 2025 Performance, High Executive Payouts, and Substantial Capital Returns
Summary
CNO Financial Group's definitive proxy statement reveals robust 2025 operating performance, leading to significant executive compensation payouts tied to outperforming TSR and substantial capital returns to shareholders.
Key Events
-
Strong Executive Performance Payouts
2023-2025 performance share awards paid out at 115.8% (Operating ROE) and 112.9% (Operating EPS) of target, after a 25% increase from a 90th percentile relative Total Shareholder Return.
-
Significant Capital Returns
The company returned $386.1 million to shareholders in 2025, including $319.9 million in share repurchases, and has $420.4 million remaining authorization.
-
Positive Operational Results
Despite a GAAP net income decrease due to non-economic factors, net operating income increased in 2025, alongside record sales growth in both Consumer and Worksite Divisions.
-
Routine Annual Meeting Proposals
Shareholders will vote on the election of nine directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor at the Annual Meeting on May 12, 2026.
Analysis
The DEF 14A filing highlights CNO Financial Group's robust operational and financial performance in 2025, which translated into above-target executive compensation. Notably, the 2023-2025 performance share awards paid out at over 110% of target, boosted by a 25% modifier due to the company's total shareholder return ranking in the 90th percentile against its peer group. The company also returned a substantial $386.1 million to shareholders in 2025, including $319.9 million in share repurchases, demonstrating a commitment to shareholder value. While GAAP net income decreased due to non-economic accounting impacts and an impairment charge, net operating income increased, providing important context for investors.
At the time of this filing, CNO was trading at $40.96 on NYSE in the Finance sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $34.63 to $44.86. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.